Three years after legalization of nonprescription pharmacy syringe sales in California: Where are we now?

Journal of Urban Health

Volumn 87, Issue 4, 2010, Pages 576-585

  Garfein, Richard S ^f   Stopka, Thomas J ^a   Pavlinac, Patricia B ^f   Ross, Alessandra ^a   Haye, B Karen ^e,f   Riley, Elise D ^b   Bluthenthal, Ricky N ^c,d  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d RAND CORPORATION   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Harm reduction; Health policy; Hepatitis C virus; HIV; Injection drug use; Syringe access

Indexed keywords

ARTICLE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGAL ASPECT; PHARMACY; PREVENTIVE HEALTH SERVICE; STATISTICS; SUBSTANCE ABUSE; UNITED STATES;

CALIFORNIA; COMMUNITY PHARMACY SERVICES; HEPATITIS C; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 77954660457     PISSN: 10993460     EISSN: 14682869     Source Type: Journal    
DOI: 10.1007/s11524-010-9463-3     Document Type: Article

References (32)

1. California Department of Public Health, Office of AIDS Fact Sheet; Injection drug users and their sex/needle-sharing partners, September 2007. Accessed on December 1,2009. Available at: http://www.cdph.ca.gov/programs/aids/ Documents/FS2527IDU2007-09-17.pdf.
2. California Department of Public Health, Office of AIDS, HIV/AIDS Case Registry Section. California HIV Injection Drug Use Exposure Cumulative Cases as of January 31, 2008. Accessed on December 1, 2009. Available at: http://www.cdph.ca.gov/data/statistics/Documents/OA-2008-01HIVAIDSMerged.pdf.
3. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999; 107(6B): 2S-9S.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714.
5. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34(1): 180-187.
6. Tseng FC, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007; 46 (3): 666-671.
7. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009; 200(8): 1216-1226.
8. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001; 91(1): 42-46.
9. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med. 2008; 70(5): 606-611.
10. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep. 1998; 113(Suppl 1): 75-80.
11. Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. 2008; 85(3): 309-322.
12. US Public Health Service, HIV prevention bulletin: medical advice for persons who inject illicit drugs (1997). Accessed on December 1, 2009. Available at: http://www.cdc.gov/idu/pubs/hiv-prev.htm.
13. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996; 86(5): 642-654.
14. Fuller CM, Galea S, Caceres W, Blaney S, Sisco S, Vlahov D. Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health. 2007; 97(1): 117-124.
15. Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr. 2005; 39(4): 471-477.
16. Legislative Counsel. State of California. Official California Legislative Information. Accessed on December 1, 2009. Available at: http://www.leginfo.ca. gov.
17. Stopka TJ, Garfein RS, Ross A, Truax S.R. Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health. 2007; 84(1): 116-125.
18. State of California, Department of Finance, E-1 Population Estimates for Cities, Counties and the State with Annual Percent Change - January 1, 2007 and 2008. Sacramento, California, May 2008. Accessed on December 1, 2009. Available at: http://www.dof.ca.gov/research/demographic/reports/estimates/e-1-2006-07/.
19. Ross, Alessandra (May 27, 2007) Injection Drug Use Policy and Programs Coordinator, CDPH. Interview. Quoted in The Center for Health Improvement, Policy Brief, August, 2007. Accessed on December 1, 2009. Available at: http://www.chipolicy.org/pdf/6037.Syringe%20Policy%20Brief.pdf.
20. Center for Health Improvement. Accessed on December 1, 2009. Available at: www.chipolicy.org.
21. Bluthenthal RN, Heinzerling KG, Anderson R, Flynn NM, Kral AH. Approval of syringe exchange programs in California: results from a local approach to HIV prevention. Am J Public Health. 2008; 98(2): 278-283.
22. Cooper E, Dodson C, Stopka TJ, Riley ED, Garfein RS, Bluthenthal RN. Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco Counties, 2007. J Urban Health. 2010 (this issue).
23. Cotten-Oldenburg NU, Carr P, DeBoer JM, Collison EK, Novotny G. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr. 2001; 27(2): 183-192.
24. Rich JD, Hogan JW, Wolf F, et al. Lower syringe sharing and re-use after syringe legalization in Rhode Island. Drug Alcohol Depend. 2007; 89(2-3): 292-297.
25. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006; 41(6-7): 777-813.
26. Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001; 91(5): 791-793.
27. Compton WM 3rd, Cottler LB, Decker SH, Mager D, Stringfellow R. Legal needle buying in St. Louis. Am J Public Health. 1992; 82(4): 595-596.
28. Lewis BA, Koester SK, Bush TW. Pharmacists' attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S46-S51.
29. Taussig J, Junge B, Burris S, Jones TS, Sterk CE. Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta, Georgia. J Am Pharm Assoc (Wash). 2002; 42(6 Suppl 2): S40-S45.
30. Coffin PO, Linas BP, Factor SH, Vlahov D. New York City pharmacists' attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health. 2000; 77(4): 781-793. (Pubitemid 32059242)
31. Riley ED, Kral A, Stopka TJ, Garfein RS, Reuckhaus P, Bluthenthal RN. Access to sterile syringes through San Francisco pharmacies and the association with HIV risk behavior among injection drug users. J Urban Health. 2010 (this issue).
32. McNeely J, Arnsten JH, Gourevitch MN. Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross- sectional survey. Harm Reduct J. 2006; 3: 8.